Adial Pharmaceuticals has filed a Form S-8 registration statement to add 1.5 million shares of common stock to its 2017 Equity Incentive Plan. This addition was approved by the company's board and shareholders at the 2024 Annual Meeting on November 12, 2024, as part of Amendment No. 6 to the plan.The registration increases the total number of shares available under the plan to 2 million. This follows previous amendments and a 1-for-25 reverse stock split effected on August 4, 2023. The additional shares are intended to provide equity incentives to employees, directors and consultants.The filing incorporates by reference Adial's recent SEC filings, including its 2023 annual report and 2024 quarterly reports. It also outlines standard indemnification provisions for directors and officers as permitted under Delaware law.

Adial Pharmaceuticals has filed a Form S-8 registration statement to add 1.5 million shares of common stock to its 2017 Equity Incentive Plan. This addition was approved by the company's board and shareholders at the 2024 Annual Meeting on November 12, 2024, as part of Amendment No. 6 to the plan.The registration increases the total number of shares available under the plan to 2 million. This follows previous amendments and a 1-for-25 reverse stock split effected on August 4, 2023. The additional shares are intended to provide equity incentives to employees, directors and consultants.The filing incorporates by reference Adial's recent SEC filings, including its 2023 annual report and 2024 quarterly reports. It also outlines standard indemnification provisions for directors and officers as permitted under Delaware law.